Oncology Peer Review On-The-Go: Molecular Profiling Practices in Pancreatic Adenocarcinoma

Podcast

CancerNetwork® dissects an article from the journal ONCOLOGY® focusing on academic and community molecular profiling practices for patients with pancreatic adenocarcinoma.

In this week’s “Oncology Peer Review On-The-Go,” we discuss an article from the May issue of the journal ONCOLOGY® titled Molecular Profiling Practices in Pancreatic Adenocarcinoma: Academic vs Community Physicians. CancerNetwork® spoke with Christine Chung, DO, from the HCA Swedish Medical Center in Englewood, Colorado, about the molecular profiling patterns she and her colleagues observed in this retrospective review. The authors found that both academic and community physicians ordered profiling about 50% of the time, which was contrary to previous reports that suggest academic centers perform molecular profiling more often.

The perspective for this article comes from Roman Groisberg, MD, a medical oncologist and director of the Sarcoma Medical Oncology Program at the Rutgers Cancer Institute in New Brunswick, New Jersey. Groisberg discussed the role of profiling in pancreatic adenocarcinoma, his thoughts on the retrospective review, and the future of profiling for this cohort of patients.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Recent Videos
Differences in pancreatic cancer responses to treatment elicits a need to better educate patients on expectations in treatment, particularly chemotherapy.
Increasing patient awareness of modifiable risk factors for pancreatic cancer may help mitigate incidence of pancreatic cancers.
It may be crucial to test every patient for markers such as BRAF V600E mutations, NRG1 fusions, and KRAS G12C mutations to help manage pancreatic cancers.
Tanios S. Bekaii-Saab, MD, emphasizes the idea of moving targeted therapies to earlier lines of treatment to further improve outcomes in pancreatic cancer.
Experts from Vanderbilt University Medical Center emphasize gathering a second opinion to determine if a tumor is resectable in patients with pancreatic cancer.
Experts from Vanderbilt University Medical Center discuss the use of intraoperative radiation therapy in a 64-year-old patient with pancreatic cancer.
Investigators are assessing the use of IORT in patients with borderline resectable or unresectable pancreatic cancer as part of the phase 2 PACER trial.
Kamran Idrees, MD, MSCI, MMHC, FACS, discusses how factors such as vessel involvement can influence the decision to proceed with surgical therapy.
Milad Baradaran, PhD, DABR, outlines the design of Mobetron as an option for administering intraoperative radiation therapy in pancreatic cancer care.
Intraoperative radiation therapy may allow surgical and radiation oncologists to collaboratively visualize at-risk areas in patients with cancer.
Related Content